Pre­ci­sion Bio wants to show there's a bet­ter way to ed­it genes — and now it has $126M in IPO cash to prove it

Af­ter spend­ing the sec­ond half of last year lay­ing the car­pet for an IPO — com­plete with a crossover round and a big part­ner­ship with Gilead — Pre­ci­sion Bio­Sciences has raised $126 mil­lion in its pub­lic de­but.

The go­ing price was $16 each for 7.9 mil­lion shares $DTIL, smack in the mid­dle of its pro­posed range but land­ing above Pre­ci­sion’s orig­i­nal pen­cilled-in goal of $100 mil­lion.

The Durham, NC-based gene edit­ing up­start is pitch­ing its ARC nu­cle­ase ap­proach as a bet­ter al­ter­na­tive to the promi­nent trio of CRISPR, TAL­EN and zinc fin­ger nu­cle­ase. Dubbed AR­CUS, the tech de­rives its name from a hom­ing en­donu­cle­ase found in al­gae called I-Crel, re­pur­pos­ing its nat­ur­al genome edit­ing abil­i­ties to cut and paste on­to cells as need­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.